The New Frontier - Your weekly science and innovation update - 13th April 2026

A bitter pill sweetened

The UK finalised a deal ensuring 0% tariffs on UK pharma and MedTech exports to the US for at least three years. In return, the UK agreed to increase NHS spending on new medicines.

Following the announcement of the deal, a GSK spokesperson said the company is pleased ​it has been finalised, adding that it provides certainty on zero tariffs for medicines and improves the British operating environment while rewarding innovation. The spokesperson said work now needs to happen "at pace" on the detailed action ​to deliver the improvements.

For the industry improved UK-US trade terms and faster NICE approvals strengthen the case for pharma companies to locate in the UK. The question is will it be enough?

UK venture capital: a robust first quarter

Preliminary figures are in. The UK venture capital market recorded a robust Q1 2026, with 715 completed deals deploying £7.25 billion in capital. This is the highest value since Q2 2022.  The average round came to approximately £15 million and a median of £1.6 million.

Three deals alone: Nscale (£1.48 billion), Wayve (£1.1 billion), and Kraken Technologies (£746 million) accounted for nearly 46% of all capital deployed. Information Technology captured 308 of 715 deals (43%) and an extraordinary 70% of total investment.

The most striking cross-cutting trend is the pervasive integration of artificial intelligence: 327 deals (46%) listed AI or Machine Learning as a vertical, making it the single most common theme across the entire dataset. AI penetration was highest in IT (67% of deals) and Healthcare (44%) but reached meaningful levels in B2B Services (33%) and Financial Services (21%).

London remains the undisputed centre of UK venture activity, accounting for 381 deals (53%) and £6.21 billion (86%) of total capital. Beyond the capital, other hubs emerge. Cambridge led non-London cities with 24 deals and £233 million, driven by its deep tech and life sciences ecosystem. Oxford, despite recording just 8 deals, deployed £97 million at an average of £19.4 million per round, the highest average outside London. Manchester (16 deals), Edinburgh (15), Bristol (14), and Birmingham (13) all recorded solid deal volumes, albeit at smaller average sizes, highlighting their underlying potential if the right support is in place.

Life sciences: concentrated capital, AI omnipresent

After three quarters of declining deal count, Q1 life sciences activity held broadly steady with 138 deals. £770.5million was raised in total. Pharmaceuticals & Biotechnology dominated with 57 deals totalling £512 million.

The geographic concentration is stark. London accounts for 38% of all deals and £301 million in capital. Cambridge follows with 14 deals and £214 million, meaning Cambridge's average deal size (£23.8 million) is 2.4 times London's (£10 million). Together these two cities represent 67% of all reported capital.

AI and machine learning appeared in 60 deals while oncology punches above its weight in capital intensity. The top 10 deals totalled £572 million or roughly 74% of all capital, with Tenpoint Therapeutics' £174 million Series B standing out as Q1's mega-round.

Company formation: digital leads, London dominates

Preliminary incorporation data shows just over 200,000 new companies formed in the UK in Q1, in line with Q1 2025. Digital and technologies led the government's industrial strategy sectors with 9,696 companies formed, followed by professional and business services (7,081) and creative industries (4,267).

London remains the epicentre for company creation with 68,879 new incorporations, followed by the South East (22,172) and North West (22,107). Geographic variances emerge by sector: in professional and business services, the North West jumps to third place behind London and the South East. In clean energy, the East Midlands sits second behind London. In defence, the South West takes joint second. In AI specifically, the North West pulls its weight in joint third with the East of England, with 30 companies formed.

OpenAI’s four-day week

OpenAI this week released a 13-page policy manifesto that amounts to a call for a partial rewiring of American capitalism. Its proposals include a public wealth fund, portable benefits, robot taxes and a four‑day workweek with no loss of pay. It is easy to dismiss this as regulatory positioning by a company seeking to shape the rules that will govern it. However, the real estate implications warrant attention.

A four‑day week upends assumptions about utilisation and space planning. Offices would be used less frequently, but more deliberately, with attendance focused on concentrated periods of collaboration, decision making, and alignment. As a result, offices matter less as places to sit and more as places to convene. Their value lies in activities that benefit from proximity: cultural reinforcement, training, communication, and collective problem solving. High‑efficiency environments that allow teams to switch rapidly between modes of work will become the norm. Flexible team areas, meeting rooms, and large town hall spaces will carry increasing weight. In this world, success is judged less by utilisation or occupancy alone and more by impact. Productivity, collaboration quality, and learning outcomes become the metrics that also matter.

In other news...

Scientists have achieved a world first by loading a complete genome onto a quantum computer, a major step toward using quantum computing to tackle biology's most complex bioinformatic challenges.

Nxera Pharma, which has major Cambridge operations at Granta Park, has clinched a second milestone payment under its multi-target collaboration with Eli Lilly. And leading quantum nations are boosting cooperation following the UK summit.

Narwhal Labs, a Bristol-based startup developing AI-powered enterprise communication tools, has announced a £20 million financing round. Founded in 2022, Narwhal has developed 'DeepBlue OS', an autonomous communications platform for enterprises. The round was led by Jonathan Swann of CFC Underwriting.

Anthropic is buying Coefficient Bio, building out its plans to bring AI into life sciences. Anthropic agreed to pay $400 million in stock for Coefficient, which was founded less than a year ago.

Across March, biopharmas lined up 10 acquisitions worth up to $31.5 billion. If the pace continues, 2026 could surpass 2025,

Blackstone announced it had raised $6.3 billion for its latest life sciences vehicle, Blackstone Life Sciences VI — the industry’s largest-ever private investment fund. It’s equal to more than half the value of new investment funds raised all last year, according to a year-end report from William Blair.

OpenAI has suspended its ambitious Stargate UK data centre project, citing high energy costs and regulatory uncertainty. The company says it will move forward when “the right conditions allow”.  The pause comes as Bisnow reports that AI companies are acquiring more office space in New York, with AI companies securing half of their 2025 leasing volume in just the first quarter.  Most AI companies are seeking flexible, short-term leases for plug and play space. Both Anthropic and OpenAI continue to burn through cash, with OpenAI expected to burn tens of billions per year for the rest of the decade, peaking at £85 billion in 2028, before achieving profitability in 2030.

Pony.ai plans to roll-out its robotaxis to over 20 cities in 2026, as it scales its fleet and expands into new markets.